Tirzepatide: what experts said, Q2 2026

Between March and June 2026, several credentialed research teams published formal positions on tirzepatide, covering durability of weight loss, safety gaps, and early signals in populations the drug was never designed for. Three items stand out: SURMOUNT-MAINTAIN read out in the Lancet^[1], an international safety review warned about muscle loss in Expert Opinion on Drug Safety^[2], and a systematic review in Endocrinology, Diabetes & Metabolism mapped the thin evidence for tirzepatide in type-1 diabetes^[3].

SURMOUNT-MAINTAIN: the dose-reduction question, answered

Horn, Aronne, Wharton and colleagues randomised 378 adults with obesity after a 60-week open-label weight-loss phase on tirzepatide. Participants either stayed on the maximum tolerated dose (10 or 15 mg), stepped down to 5 mg, or switched to placebo for another 52 weeks^[1]. At week 112 the full-dose group held a 21.9% total weight reduction, the 5 mg group 16.6%, and placebo 9.9%. Only 8% on full-dose tirzepatide regained half or more of their lost weight, versus 67% on placebo. The trial enrolled 441 participants in the open-label phase, with 345 (91%) completing the full 112 weeks.

The study design answers a question the earlier SURMOUNT-4 discontinuation trial left open^[4]. SURMOUNT-4 showed what happens when tirzepatide stops entirely: the placebo arm regained 14 percentage points of body weight between week 36 and week 88. SURMOUNT-MAINTAIN tested the middle ground. Stepping down to 5 mg is not stopping, and the numbers show it: the 5 mg group regained some weight compared to the full-dose arm, but kept well ahead of placebo, with only a quarter of participants regaining half or more of their initial loss.

Andre Scheen, writing the accompanying Lancet editorial, framed the result: "SURMOUNT-MAINTAIN now provides information on the effect of dose reduction on the maintenance of bodyweight reduction for the first time in a dedicated RCT"^[1]. The practical takeaway is that clinicians now have a middle option between full-dose continuation and the sharp regain seen on discontinuation. For patients who tolerate tirzepatide well but want to reduce injection burden or cost, 5 mg weekly preserves roughly two-thirds of the peak loss. That is new data, and it is from a dedicated randomised trial rather than a post-hoc subgroup analysis.

SURMOUNT-MAINTAIN now provides information on the effect of dose reduction on the maintenance of bodyweight reduction for the first time in a dedicated RCT.

Safety reviewers flag sarcopenia risk

In a June 2026 review in Expert Opinion on Drug Safety, Janic, Rizzo and colleagues examined tirzepatide's full adverse-event spectrum: the familiar gastrointestinal signals, the rarer gallbladder and thyroid risks, and a newer concern around skeletal muscle loss^[2]. Their central argument is that "clinical management must evolve toward precision phenotyping to individualise patient risk-benefit trajectories." In plainer terms: the same dose does not suit every patient, and the field needs functional outcome data (grip strength, falls, mobility) alongside the weight numbers.

The sarcopenia point matters because rapid weight loss on any intervention costs both fat and lean mass. Tirzepatide's headline losses of 20% or more amplify that trade-off. If long-term functional outcomes are not tracked, the disease-modifying benefit could be partly offset by frailty, particularly in older adults. The SURMOUNT and SURPASS programmes measured body weight and metabolic endpoints, but grip strength, gait speed, and fall incidence were not primary or secondary endpoints. The review stops short of calling this a crisis, but it is a gap the trial programme has not yet closed.

The broader safety profile remains consistent with what the EMA's Mounjaro EPAR and the US prescribing label have described since approval^[4]: gastrointestinal adverse events (nausea, diarrhoea, vomiting, constipation) dominate, gallbladder and pancreatic events are rarer but monitored, and the US boxed warning on thyroid C-cell tumours in rats remains unchanged. What Janic and Rizzo add is the argument that the next generation of trials should measure function, not just weight.

Type-1 diabetes: early signal, thin evidence

Acucella and Caponio reviewed randomised and real-world evidence on tirzepatide as an adjunct to insulin in adults with type-1 diabetes and overweight or obesity^[3]. The data so far: one small 12-week randomised trial showing a between-group HbA1c difference of about 0.4 percentage points and a mean weight loss of 10.3 kg (8.8%), plus a handful of observational studies reporting larger reductions over longer follow-up. Insulin requirements dropped by roughly 30 to 35% across studies.

The authors are honest about the limits. Evidence certainty is low to very low. The observational data carry serious risk of bias. Diabetic ketoacidosis monitoring has been inconsistent across studies, and no standard definition was used. Their phrase: "the absence of a clear safety signal should be interpreted strictly as absence of evidence, not evidence of absence." Larger dedicated trials are needed before tirzepatide has a definitive role in type-1 diabetes^[3].

What is not in these reviews

None of these publications addresses the cardiovascular-outcomes question in obesity without diabetes. The SUMMIT trial in heart failure with preserved ejection fraction reported a 38% reduction in the composite endpoint^[5], but a dedicated MACE outcomes trial matching what SELECT did for semaglutide has not yet read out. That remains the single biggest gap in tirzepatide's evidence base.

None of the reviews examined counterfeit or grey-market tirzepatide, which remains a separate and growing concern outside the regulated supply chain. And none revisited the paediatric indication, even though the EMA CHMP issued a positive opinion for Mounjaro in adolescents and children aged 10 and over with type-2 diabetes back in December 2025. That extension is still working through national reimbursement decisions across the EU.

Practical context

This quarter's expert output adds up to: the drug works, the durability data are now stronger, and the safety conversation is getting more specific. Sarcopenia risk and the type-1 diabetes off-label signal are new areas where the field is asking questions faster than trials can answer them. For readers following tirzepatide on this site, or checking how the drug is regulated in their country, the message from credentialed experts this quarter is: keep watching, stay cautious, and talk to a clinician before acting on any of this.